Imaging First Limited, established in the UK in 2012, selling ultrasound systems, probes, QA and service are now the UK authorised distributors for iCAD, the market leader in multi-vendor computer-aided detection of breast cancer with over 7,000 installations worldwide.
Profound AI is a precise, powerful, and proven deep learning, artificial intelligence platform that supports radiologists with reading 2D mammography and breast tomosynthesis.
Profound AI for 2D and tomosynthesis
Challenge – Mammography reading can be complicated, especially in dense breasts. Tomosynthesis reading can be time consuming, and radiologists are confronted by workload issues to read extensive amounts of data while maintaining high accuracy for detecting malignancies.
As incidence rates of breast cancer continue to rise, it is increasingly important to improve cancer detection while reducing unnecessary recalls resulting from false positives.
Solution – Designed for radiologists, ProFound AI for 2D Mammography* and ProFound AI for Tomosynthesis is revolutionizing reading paradigms and provides a transformative solution to address these challenges.
The high-performing cancer detection and workﬂow solution rapidly and accurately analyses each image, detecting both malignant soft tissue densities and calciﬁcations with unrivalled accuracy.
ProFound AI for Tomosynthesis is proven to assist radiologists in addressing the challenges of reading cases by improving cancer detection rates, while simultaneously reducing false positives and unnecessary patient recalls.
Certainty of Finding and Case Scores – The ProFound AI algorithm is trained to detect malignant soft tissue densities and calciﬁcations for both mammography and tomosynthesis. Certainty of Finding and Case Scores are assigned to each detection and each case respectively. The scores are represented on a 0% to 100% scale. A higher score indicates a higher level of conﬁdence in the malignancy of the detection or case.
Platform – The ProFound AI platform for breast imaging includes detection solutions for 2D mammography, tomosynthesis and density assessment. It runs on the industry leading PowerLook server, a ﬂexible and reliable DICOM platform, easily integrated with image modalities, mammography review workstations, PACS, and image storage systems. With the latest GPU technology, the algorithm rapidly processes cases, ensuring results are readily available to radiologists.
Profound AI Risk
Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is truly personalised, based only on a screening mammogram.
It uniquely combines a range of risk factors, including age, breast density and subtle mammographic features, offering superior performance in assessing short-term risk compared to traditional breast cancer risk models, the package aids in the decision-making process for physicians to create a personalised screening and surveillance plan for each individual.
Contact us for a further information and/or a demonstration.
This news story has been sponsored by the companies concerned and does not represent the views or opinions of RAD Magazine.